🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Pharma stock in focus after it enters into an agreement with Takeda Pharma for Vonoprazan tablets

Published 21-06-2024, 02:33 pm
Pharma stock in focus after it enters into an agreement with Takeda Pharma for Vonoprazan tablets
SUN
-

Pharma Stock engaged in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and Active Pharma Ingredients in focus upon signing pact with Takeda Pharmaceutical Company Limited.

With a market capitalization of Rs. 3,54,085 Crores, the shares of Sun Pharmaceuticals (NS:SUN) Industries Limited were trading at Rs. 1,475.80 per equity share, up 0.48 percent from its previous day’s close price of Rs. 1,470.45.

Is Sun Pharma a buy or sell? Click here to get an InvestingPro subscription for a special discount of 74% at an unbelievable price of only Rs 182 per month

The above link works best from a laptop/desktop and not apps.

Sun Pharmaceuticals Industries Limited has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Limited (Takeda) to commercialise Vonoprazan tablets 10 mg, 20 mg in India under the brand name “Voltapraz”

Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders like Gastroesophageal Reflux Disease, etc.

In November 2023, Vonoprazan was approved by the US FDA for healing and maintenance of healing of all grades of Erosive esophagitis and relief of heartburn associated with Erosive esophagitis and in combination with amoxicillin and clarithromycin or amoxicillin alone for the

treatment of Helicobacter pylori (H. pylori) infection in adults. The drug is approved in India for treatment of adults with Reflux esophagitis and other acid peptic disorders.

Gastroesophageal Reflux Disease (GERD) is common in India irrespective of geographical or rural/urban location. Prevalence of GERD in Indian population ranges from 5 percent to 28.5 percent. Risk factors for GERD include age, body mass index (BMI), non-vegetarian diet, tea/coffee intake, tobacco, and alcohol consumption

Sun Pharmaceutical Industries Limited is one of the largest pharmaceutical companies in India the fourth largest specialty generic company in the world, it is engaged in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and Active Pharma Ingredients.

Sun Pharmaceutical Industries Limited has Manufacturing capabilities across injectables, sprays, ointments, creams, liquids, tablets and capsules.

It has a diversified revenue base with India Branded Formulations contributing 32 percent, US Formualtions 31 percent, Emerging Markets 18 percent, API & Others 5 percent and 14 percent Rest of the World.

Its Revenue from operations grew by 10.14 percent from Rs. 10,725 Crores in Q4FY23 to Rs. 11,813 Crores in Q4FY24, accompanied by profits of Rs. 2,016.78 Crores to Rs. 2,666.59 Crores.

Introducing InvestingPro

Through InvestingPro, you can beat the markets with premium insights:

  • Find Undervalued/Overvalued Stocks: Reveal the unbiased Fair Value of any stock based on 1,200+ premium metrics, covering 180,000+ companies worldwide.
  • Instant Financial Bottom Line: Make fully-informed investing decisions with ProTips, bite-size insights that flag risks and rewards on any stock.
  • Get AI-Enhanced Stock Picks: Receive regularly updated ProPicks for any investing strategy, each with a proven track record to beat the S&P 500
  • Boost Your Picks with Data: Instantly see a company's long-term sustainability and Financial Health to know if it's truly a solid investment.
  • Always Pick the Winner: Make instant Peer Comparisons based on over a dozen valuation benchmarks to ensure you always select a top dog.

Now, coming to the great news! For the benefit of our users, we have reduced the prices on all of our Pro and Pro+ plans by almost 74% for a limited period.

Click here to get an InvestingPro subscription for a special discount of 74% at an unbelievable price of only Rs 182 per month

The above link works best from a laptop/desktop and not apps.

Written by: Bharath K.S

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma stock in focus after it enters into an agreement with Takeda Pharma for Vonoprazan tablets appeared first on Trade Brains.

Read More

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.